Takeda Pharmaceutical Company Limited TKPYY
("Takeda") today announced the acquisition of a biologics manufacturing
facility located in Brooklyn Park, Minnesota, U.S., from Baxalta US Inc
BXLT. Takeda intends to use the facility primarily for the
manufacture of Entyvio® (vedolizumab) and other biologic
products, allowing the company to maximize global efficiencies and
further enhance the product's supply chain flexibility.
"Takeda's focus is providing patients access to quality therapies," said
Thomas Wozniewski, Global Manufacturing and Supply Officer at Takeda.
"Acquiring the state of the art Brooklyn Park facility and gaining
access to a highly experienced and dedicated team is a very important
strategic benefit for Takeda that reinforces and expands upon our global
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in